— AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This is compared to $0.45 per share expected.
— Total revenue increased by 20% to $6.41 billion versus $6.18 billion expected. This is driven by a 16% jump in product sales.
— Oncology sales jumped by 46% and respiratory sales grew by 15%. Biopharmaceuticals sales increased by 12% and new CVRM sales rose by 8% while sales in other medicines fell by 9%.
— Looking ahead into the full year 2019, the company reiterates its core earnings guidance in the range of $3.50 to $3.70 per share.
— The core operating profit for fiscal 2019 is predicted to increase ahead of product sales.
— For the full year, capital expenditure is anticipated to be broadly stable and restructuring expenses are targeted to reduce versus the prior-year.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
